Hologic Inc

Análisis de la acción Hologic Inc (HOLX)

$76.010

+0.365 (+0.48%)Al cierre

Loading chart…
High
76.070
Open
76.010
VWAP
76.03
Vol
102.03M
Mkt Cap
17.32B
Low
76.000
Amount
7.76B
EV/EBITDA, TTM
13.12

Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.

AI analysis of Hologic Inc (HOLX)

hold

Hologic Inc (HOLX) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. While the technical indicators are mildly positive, the lack of significant positive catalysts, a recent analyst downgrade, and declining financial metrics suggest a cautious approach. Holding the stock or exploring other opportunities may be more prudent.

Analyst Ratings (19)

+2.04% upside
Buy
14 Buy
5 Hold
0 Sell
Current: 76.01
Mínimo
76.00
Promedio
77.56
Máximo
79.00

Evercore ISI

2026-01-05

Precio objetivo

$78

In Line

BNP Paribas Exane

2025-11-21

Precio objetivo

$79

Neutral

Morgan Stanley

2025-11-10

Precio objetivo

$76

Equal Weight

Mizuho

2025-10-23

Precio objetivo

$78

Neutral

Stephens

2025-10-22

Precio objetivo

$76

Equal Weight

Métricas de valoración

The current forward P/E ratio for Hologic Inc (HOLX) is 16.75, compared to its 5-year average forward P/E of 18.04.

Forward P/E

Fair
5Y Average P/E
18.04
Current P/E
16.75
Sobrevalorada
21.08
Infravalorada
15.00

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
13.43
Current EV/EBITDA
13.12
Sobrevalorada
15.34
Infravalorada
11.52

Forward P/S

Fair
5Y Average P/S
4.26
Current P/S
3.81
Sobrevalorada
4.80
Infravalorada
3.73

Alphio AI Price Scenarios for HOLX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%HOLX

$90.01

Precio del escenario

B

Base

Base · 50%HOLX

$75.18

Precio del escenario

B

Bear

Bear · 25%HOLX

$64.21

Precio del escenario

Whales holding HOLX

M

MIV Asset Management AG

+ HoldingHOLX

+10.92%

3M Return

H

HBK Investments L.P.

+ HoldingHOLX

+4.39%

3M Return

A

Alberta Investment Management Corporation

+ HoldingHOLX

+4.21%

3M Return

C

Cinctive Capital Management LP

+ HoldingHOLX

+2.26%

3M Return

M

Manulife Asset Management

+ HoldingHOLX

+1.87%

3M Return

Q

Quinn Opportunity Partners LLC

+ HoldingHOLX

+1.76%

3M Return

Cronología de eventos

2026-06-16 (ET)

13:30:00

Hologic Wins in Germany, Siemens Prohibited from Selling Mammography Systems

2026-04-07 (ET)

09:30:00

Hologic Completes Acquisition by Blackstone and TPG, Valued at Up to $79 per Share

2026-04-06 (ET)

17:20:00

Blackstone and TPG to Acquire Hologic, Deal Expected by April 7

17:20:00

Blackstone and TPG Acquire Hologic, Deal Expected by April 7

Noticias

HOLX FAQ — answered by Alphio AI

Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm. It operates in the Healthcare sector (X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPA industry).

Hologic Inc (HOLX) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. While the technical indicators are mildly positive, the lack of significant positive catalysts, a recent analyst downgrade, and declining financial metrics suggest a cautious approach. Holding the stock or exploring other opportunities may be more prudent.

19 analysts cover HOLX: 14 rate it Buy, 5 Hold and 0 Sell. The average price target is 77.56.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis